Bayer's acquisition of Monsanto for $62 billion, announced in 2016 and completed in 2018, is now widely regarded as one of the most expensive mistakes in modern agribusiness history. Led by then-CEO Werner Baumann, the deal aimed to create a global agricultural powerhouse by combining Monsanto's seed technology and digital farming capabilities with Bayer's crop protection portfolio. However, billions of dollars in litigation tied to Roundup, Monsanto's flagship herbicide, transformed what was expected to be a growth-driven acquisition into a cautionary tale for corporate dealmakers worldwide.

At the time, Bayer argued that the acquisition would position the company as the undisputed leader in agricultural innovation. The merger brought together complementary businesses spanning seeds, biotechnology, precision agriculture, and crop protection products.

Yet investors immediately expressed concern. Following reports of Bayer's interest in Monsanto, the German company lost roughly $15 billion in market value, reflecting widespread skepticism about both the purchase price and the risks attached to the deal.

Bioinputs

Biologicals Are Booming, Yet 38.5% of the Market Still Doesn't Trust Them

Despite those concerns, Bayer moved forward with what became the largest acquisition in its more than 160-year history.

The roots of Bayer's troubles can be traced back to a warning sign that many analysts believed was already visible before the transaction closed.

In 2015, the International Agency for Research on Cancer, part of the World Health Organization (WHO), classified glyphosate as "probably carcinogenic to humans." Although regulatory agencies including the U.S. Environmental Protection Agency (EPA) and European authorities continued to support the safety of glyphosate-based products, the classification sparked intense legal scrutiny.

That scrutiny quickly evolved into litigation.

In 2018, just months after Bayer completed the Monsanto acquisition, a California jury ruled in favor of a groundskeeper who claimed that Roundup caused his cancer. The verdict opened the floodgates for thousands of similar lawsuits across the United States.

What initially appeared to be a manageable legal challenge soon became one of the largest corporate litigation battles in modern history.

The financial consequences have been staggering.

Since acquiring Monsanto, Bayer has spent more than $10 billion settling claims related to Roundup. The company has also set aside nearly $14 billion in litigation provisions, highlighting the ongoing financial burden associated with the lawsuits.

The impact on shareholders has been severe. Bayer's market value today remains below the amount it paid for Monsanto, making the acquisition a textbook example of how legal liabilities can overwhelm the strategic benefits of a corporate merger.

For many investors, the deal represents one of the clearest examples of value destruction caused by underestimated litigation risk.

The Paradox: The Agricultural Business Actually Performed Well

Ironically, Bayer's core agricultural strategy was not the problem.

The company's Crop Science division has delivered stronger growth than several other business segments since the acquisition. Since 2018, sales within the agricultural unit have increased by roughly 2% annually on average, outperforming Bayer's pharmaceutical business, which has experienced relatively flat growth.

This paradox underscores a key lesson for agribusiness executives and investors: the acquisition itself generated operational benefits, but the legal liabilities attached to Monsanto dramatically altered the economics of the transaction.

Had Bayer negotiated a lower purchase price, obtained specialized litigation insurance, or conducted deeper legal risk assessments, analysts argue that the outcome might have been significantly different.

Today, the Bayer-Monsanto transaction is studied in business schools and boardrooms as a landmark example of the importance of due diligence in major acquisitions.

The case carries particular relevance for companies whose products reach millions of consumers, including food manufacturers, agricultural input suppliers, pharmaceutical firms, and industrial producers.

For corporate leaders, the lesson is clear: evaluating revenue potential, market share, and operational synergies is no longer enough. Legal exposure, regulatory uncertainty, and reputational risk must also be central components of any acquisition strategy.

Ten years after Bayer first announced its pursuit of Monsanto, the acquisition remains one of the most debated transactions in agribusiness history.

While the deal helped strengthen Bayer's agricultural footprint and reinforced its position in the global crop input market, it also generated one of the largest legal liabilities ever associated with a corporate takeover.